One-carbon is receiving a seed investment
One-carbon is receiving a seed investment from its founders to strengthen the financial situation and secure continuous pre-clinical development of MTHFD2 inhibitors.
AACR21 virtual meeting
Prof Thomas Helleday presents MTHFD2 and other emerging targets such as PKMYT1, MTH1 and Pol Theta at the AACR21 virtual meeting.